首页 | 本学科首页   官方微博 | 高级检索  
     

多柔比星心脏毒性机制及防治研究进展
引用本文:陈芾珩,刘元生. 多柔比星心脏毒性机制及防治研究进展[J]. 肿瘤研究与临床, 2008, 20(4): 285-288
作者姓名:陈芾珩  刘元生
作者单位:广东省汕头市汕头大学医学院第一附属医院血液科,515041
摘    要:多柔比星(ADM)是一种广谱、高效的蒽环类抗肿瘤药物,长期应用容易导致累积性、不可逆性心脏病变.有关ADM心脏毒性的机制较复杂,主要涉及氧化应激、线粒体病变、心肌细胞凋亡等.近年来一系列减少ADM心脏毒性而不影响其抗肿瘤活性的措施被人们采用.文章就ADM心脏毒性的发病机制及防治措施方面的进展作一综述,期望为改善肿瘤患者的长期生存率提供借鉴.

关 键 词:多柔比星  药物毒性  心脏
收稿时间:2008-10-27

The development of mechanism and prevention of Adriamycin-induced cardiotoxicity
CHEN Fei-heng,LIU Yuan-sheng. The development of mechanism and prevention of Adriamycin-induced cardiotoxicity[J]. Cancer Research and Clinic, 2008, 20(4): 285-288
Authors:CHEN Fei-heng  LIU Yuan-sheng
Affiliation:CHEN Fei-heng LIU Yuan-sheng
Abstract:Adriamycin is an effective and broad-spectrum anthracycline antineoplastic agent.However,long-term therapy with adriamycin is associated with a high incidence of cumulative and irreversible cardiomyopathy. Mechanisms about adriamycin-induced cardiotoxieity are complicated, including oxidative stress,mitochondrionopathy,cardiac apoptosis,and so on.For the past few years,a series of measures aye used,which attenuate the cardiotoxicity and uninfluence the antitumor effects.The review focuses on the mechanism and prevention of adriamycin-induced cardiotoxicity in order to improve the long term survival rate of neoplastic patient.
Keywords:Doxorubiein  Drug toxicity  Heart
本文献已被 维普 万方数据 等数据库收录!
点击此处可从《肿瘤研究与临床》浏览原始摘要信息
点击此处可从《肿瘤研究与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号